Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)

Trial Profile

Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Ankylosing spondylitis; Anterior uveitis; Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms C-VIEW
  • Sponsors UCB Biopharma
  • Most Recent Events

    • 31 Jul 2018 Planned End Date changed from 1 Mar 2020 to 1 Jan 2020.
    • 31 Jul 2018 Planned primary completion date changed from 1 Jan 2020 to 1 Dec 2019.
    • 19 Feb 2018 Planned End Date changed from 1 Apr 2020 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top